Rheumatoid Arthritis Clinical Trial
— AutoDECRAOfficial title:
Phase 1 Study of Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis
Verified date | November 2023 |
Source | Newcastle University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a study which will look at safety, feasibility and acceptability of a new therapy called tolerogenic dendritic cells (TolDC), derived from the patient's own white blood cells, which will be injected into the knee joints of rheumatoid arthritis patients, using a procedure called arthroscopy (a camera examination of a joint). The investigators are also looking to see if the drug has any effect on the disease activity (if it can help in RA) and whether the drug can affect the immune system. The investigators aim to treat 12 patients in total, 9 with TolDC and 3 with a control treatment. Three doses of TolDC will be tested, 3 patients per dose. Subjects will have RA and at least one swollen knee joint. They will undergo a knee ultrasound scan, fill in a series of questionnaires, have their knee aspirated (fluid taken out) and finally undergo a procedure called leukapheresis (removal of white blood cells) from which the treatment will be manufactured. Subsequently they will undergo 3 arthroscopies (camera examination of the knee joint) over a period of about 12 weeks. On the first arthroscopy they will have the TolDC injected into their knee joint. They will then spend the night at the Clinical Research facility for observation. Over the next 5 days they will be telephoned daily by the study doctor to check how they are, and will be reassessed if needed. About 2 weeks later they will have their second arthroscopy to look for effects of treatment, and the third will take place at 13 weeks (end of study) or sooner if the knee appears to get worse.
Status | Completed |
Enrollment | 14 |
Est. completion date | November 2018 |
Est. primary completion date | November 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Able and willing to give informed consent and to comply with the study protocol - At least 6 month's disease duration - ACR Functional Class I-III - Age 18 years or over - Active disease, including an inflamed (native) knee joint - Failure (or intolerance of) at least one disease modifying anti-rheumatic drug (DMARD), including current therapy - Morning stiffness in the target joint = 30 minutes - Willing and able to undergo arthroscopic procedures under local anaesthetic - Stable dose of non-steroidal anti-inflammatory drug (NSAID) or corticosteroid (prednisolone=10mg) for =4 weeks - No intramuscular glucocorticoid administration for = 6 weeks - Stable dose of disease-modifying anti-rheumatic drug (DMARD) for =8 weeks Exclusion Criteria: - Use of other investigational medicinal products within 30 days prior to study entry (defined as date of recruitment into study) - Patients who have received rituximab therapy and whose B-cell count remains below the normal range. Patients who have received any other cell depleting therapies and whose cell counts have not returned to the normal range, at the discretion of the principal investigator. - Serious or unstable co-morbidity deemed unsuitable by PI, eg. COPD, cardiac failure - History of malignancy (except treated basal cell carcinoma of skin) - Known active infection at screening visit or at baseline (except fungal nail infection) - Infection requiring hospitalization or IV antibiotics within 6 weeks of baseline - Immunization with live vaccine within 6 weeks of baseline - History of recurrent or chronic infection - History of hepatitis B or C, syphilis, HIV or HTLV-1/2 infections - Injection of target joint with glucocorticoids within 6 weeks of baseline - Hb<10g/dL; neutrophils< 2.00 x109/L; platelets <150x109/L; ALT/ALP>2x upper limit of normal; elevated serum creatinine at screening visit. - Major surgery within 8 weeks of baseline or planned within 3 months from baseline - Pregnancy, or women planning to become pregnant within the study period, or women who are breast feeding - Females or males of child bearing potential unwilling to use adequate contraception for duration of study - Patients taking anticoagulants - Known hypersensitivity to local or systemic corticosteroid therapy or local anaesthetic. - Poor venous access or medical condition precluding leukapheresis |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Newcastle University | Newcastle upon Tyne |
Lead Sponsor | Collaborator |
---|---|
Newcastle University | Arthritis Research UK, Newcastle-upon-Tyne Hospitals NHS Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The proportion of patients experiencing AEs and SAEs following the intra-articular administration of TolDC. | within 3 months of injection | ||
Secondary | • The proportion of RA patients who enter the study, from whom GMP-grade TolDC of sufficient quality can be prepared (the success rate of the TolDC preparation procedure). | Within one week of donation of blood for extraction of TolDC | ||
Secondary | • The proportion of patients who grade the trial and its related procedures as acceptable. | Trial participants will assess acceptability of study specific procedures via an 'acceptability questionnaire' administered at the last study visit | At final study visit, 3 months after study intervention. | |
Secondary | Systemic RA disease activity | Disease Activity Score using 28 joints (DAS28) | At baseline and at 7, 14 and 91 days post intervention | |
Secondary | Knee function | Function will be assessed using the Health Assessment Questionnaire (HAQ), a standard instrument used in RA | At baseline and at 7, 14 and 91 days post-intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |